Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Amid Iran war, 53 of Israel's future scientists showcase projects in Jerusalem contest - 2In a scientific first, biologists recorded a wild wolf potentially using tools
- 3Gulf aluminum output tumbles on Iran war
- 4'Everyone in this prison has had family killed or shot'
- 5'It's doing badly': Fears grow for whale stuck off Germany's coast
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- Germany ready to assist Syria's reconstruction, says foreign minister
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- Ukrainian foreign minister appeals for funds for drones
- Vote In favor of Your Favored Keeping an eye on
- Israeli forces kill one person in series of attacks on southern Lebanon
